ProteMix.co.nz

Title

Diabetic drug development for diabetes mellitus, Protemix, New Zealand

Description

Protemix discovers and develops novel therapies for cardiovascular disease, diabetes mellitus and other metabolic disorders and diseases. The Company combines a productive drug discovery programme with the expertise of a world-class team of diabetes researchers and the clinical focus of dedicated diabetes physicians. This combination has enabled Protemix to rapidly develop several new therapies aimed at impeding the progression of diabetes and its complications. The Company’s lead compound, Laszarin™, is currently undergoing Phase IIb trials as a treatment for diabetic heart disease. Protemix has several other drug candidates in various stages of pre-clinical development.

Protemix is a world leader in protein chemistry and has developed proprietary technologies to rapidly and systematically “mine” the human proteome for diabetes-related peptides. These have already resulted in the discovery of two novel peptide hormones which play roles in the mechanisms of insulin secretion and islet cell growth.

Protemix has developed significant expertise in the mechanisms of diabetes. This proprietary knowledge of the disease has enabled Protemix to develop a new class of therapies for diabetic heart disease in which the treatment of the most common diabetic complication is decoupled from glycemic control. Protemix’ knowledge of the mechanisms of insulin resistance has led to the identification of a peptide hormone with the potential to suppress insulin resistance. Protemix believes its knowledge of diabetes will result in a higher probability of drug development success than historically has been seen in the field.

read more

Additional Information



Retrieved from "http://aboutus.com/index.php?title=ProteMix.co.nz&oldid=24941786"